Veracyte, Inc.: Guggenheim cuts target price to $35 from $65
VCYT•Guggenheim cut its target price for Veracyte to $35 from $65.
Related News

Telesat secures lender standstill through Jan. 18 to address debt maturities
TSAT•

KORU Medical raises 2026 revenue guidance to $48 million-$48.5 million
KRMD•

Nasdaq halts trading in FCDH pending news
FCDH•

Nasdaq halts Pacira BioSciences trading pending news
PCRX•

Shell starts gas production at Rosmari-Marjoram project in Malaysia
SHEL•